BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of investors of Eagle Pharmaceuticals Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) concerning the Company and its officers’ possible violations of federal securities laws.
Eagle is a specialty pharmaceutical company that focuses on the development and commercialization of injectable products primarily in the critical care and oncology areas in the United States.
On February 25, 2016, responding to inquiries about the pending New Drug Application (“NDA”) for the Company's anticoagulant drug KANGIO, Eagle’s CEO stated, “We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2.”
However, on March 18, 2016, Eagle disclosed that the FDA did not approve the NDA because it needed “additional information” regarding the substances used in KANGIO.
On this news, Eagle stock fell nearly 19% to close at just $43.50 per share on March 18, 2016.
If you purchased Eagle securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.